• 1
    Druker BJ, Guilhot F, O’Brien SG, et al . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 240817.
  • 2
    de Lavallade H, Apperley JF, Khorashad JS, et al . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26: 335863.
  • 3
    Talpaz M, Silver RT, Druker BJ, et al . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 192837.
  • 4
    Volpe G, Panuzzo C, Ulisciani S, et al . Imatinib resistance in CML. Cancer letters. 2009; 274: 19.
  • 5
    Weisberg E, Manley PW, Breitenstein W, et al . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer cell. 2005; 7: 12941.
  • 6
    Shah NP, Tran C, Lee FY, et al . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399401.
  • 7
    Puttini M, Coluccia AM, Boschelli F, et al . In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer research. 2006; 66: 1131422.
  • 8
    Warner SL, Stephens BJ, Von Hoff DD. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep. 2008; 10: 1229.
  • 9
    Ikezoe T, Yang J, Nishioka C, et al . A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Molecular Cancer Ther. 2007; 6: 18517.
  • 10
    Harrington EA, Bebbington D, Moore J, et al . VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10: 2627.
  • 11
    Giles FJ, Cortes J, Jones D, et al . MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007; 109: 5002.
  • 12
    Gontarewicz A, Balabanov S, Keller G, et al . Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008; 111: 435564.
  • 13
    Cortes-Franco J, Dombret H, Schafhausen P, et al . Danusertib hydrochloride (PHA-739358), a multi-kinase Aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. ASH Annual Meeting. Washington : Blood J.; 2009. p. 864.
  • 14
    Dai Y, Chen S, Venditti CA, et al . Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood. 2008; 112: 793804.
  • 15
    Fiskus W, Wang Y, Joshi R, et al . Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008; 14: 610615.
  • 16
    Donato NJ, Fang D, Sun H, et al . Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol. 2010; 79: 68897.
  • 17
    Fu J, Bian M, Jiang Q, et al . Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007; 5: 110.
  • 18
    Marumoto T, Honda S, Hara T, et al . Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem. 2003; 278: 5178695.
  • 19
    Hoar K, Chakravarty A, Rabino C, et al . MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007; 27: 451325.
  • 20
    Sells T, Ecsedy J, Stroud S, et al . MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. Philadelphia : American Association for Cancer Research; 2008; 237.
  • 21
    Carew JS, Nawrocki ST, Krupnik YV, et al . Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood. 2006; 107: 22231.
  • 22
    Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000; 95: 3498505.
  • 23
    Swords RT, Kelly KR, Smith PG, et al . Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010; 115: 3796800.
  • 24
    Nawrocki ST, Carew JS, Maclean KH, et al . Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008; 112: 291726.
  • 25
    Carew JS, Nawrocki ST, Reddy VK, et al . The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res. 2008; 68: 478390.
  • 26
    Carew JS, Nawrocki ST, Kahue CN, et al . Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007; 110: 31322.
  • 27
    Di Bacco A, Keeshan K, McKenna SL, et al . Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. Oncologist. 2000; 5: 40515.
  • 28
    Wendel HG, de Stanchina E, Cepero E, et al . Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA. 2006; 103: 74449.
  • 29
    Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004; 432: 30715.
  • 30
    O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110: 22429.
  • 31
    Shah NP, Skaggs BJ, Branford S, et al . Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007; 117: 25629.
  • 32
    Chen Z, Naito M, Hori S, et al . A human IAP-family gene, Apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1999; 264: 84754.
  • 33
    Hao Y, Sekine K, Kawabata A, et al . Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol. 2004; 6: 84960.
  • 34
    Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem. 2005; 280: 17482.
  • 35
    Sung KW, Choi J, Hwang YK, et al . Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2007; 13: 510914.
  • 36
    Pohl C, Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell. 2008; 132: 83245.
  • 37
    Young MA, Shah NP, Chao LH, et al . Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006; 66: 100714.
  • 38
    Carter TA, Wodicka LM, Shah NP, et al . Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA. 2005; 102: 110116.
  • 39
    Marumoto T, Zhang D, Saya H. Aurora-A – a guardian of poles. Nat Rev Cancer. 2005; 5: 4250.
  • 40
    Martin SJ. An Apollon vista of death and destruction. Nat Cell Biol. 2004; 6: 8046.
  • 41
    Quintás-Cardama A, Gibbons DL, Kantarjian HM, et al . Mutational analysis of chronic phase chronic myeloid leukemia (CMLCP) clones reveals heightened BCR-ABL1 genetic instability in patients failing sequential imatinib and dasatinib therapy. ASH Annual Meeting Abstracts. Washington : Blood J.; 112: 2114.